PDSB
PDS Biotechnology·NASDAQ
--
--(--)
--
--(--)
5.30 / 10
Netural
Analyst consensus leans strongly bullish with two analysts issuing Strong Buy ratings, yet their historical win rates vary widely (28.6% for HC Wainwright, 100% for B. Riley). Fund flow is robust (7.38/10) with positive capital trends, but the mismatch between bullish analyst views and negative price action necessitates careful risk assessment before committing capital.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-13
InstitutionHC Wainwright & Co.
Times predicted7
Historical Win Rate28.6%
What is the analyst consensus for PDSB?
- PDSB holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.30/10 (Netural).
